A Cancer Drug For Parkinson’s? New Study Raises Hope, Draws Criticism

Home / A Cancer Drug For Parkinson’s? New Study Raises Hope, Draws Criticism

A leukemia drug may have cleared another hurdle as a potential treatment for Parkinson’s disease.

But critics say it’s still not clear whether the drug, nilotinib (brand name Tasigna), is truly safe or effective for this use.

In a study of 75 people with Parkinson’s, nilotinib appeared to improve quality of life and boost the chemical dopamine, a team from Georgetown University Medical Center reported Monday in JAMA Neurology.

“We are seeing signals that this may be a potential treatment for our Parkinson’s disease patients,” says Dr. Fernando Pagan, director of the medical center’s movement disorders program.

Full story at NPR

, , , , ,

About Author

about author

Care CEUs

CareCEUs provides high quality, affordable online ceus to nursing home administrators and assisted living personnel.